Image from: https://doi.org/10.1016/j.bbapap.2014.08.016
Antibodies derived from llamas, called nanobodies, comprise only a small part (a single domain) of conventional antibodies, yet possess full antigen-binding capacity. These nanobodies have shown great potential both as structural tools and as therapeutic agents in a number of diseases caused by protein dysfunction.
A study by Dr. Erwin De Genst and Dr. Marija Iljina reports that llama-derived nanobodies – essentially miniature antibodies – might find therapeutic application in Parkinson’s disease. The nanobodies can bind to harmful protein clumps in the brain, called oligomers, to neutralize toxicity and help prevent cell death. Furthermore, they found that the nanobodies are able to slow down the oligomer’s aggregation reaction.
We are happy to announce that in the near future, Capra Science farm will be housing llamas for development of nanobodies. More information will follow shortly.
The source of the study: https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-017-0390-6
Antibodies derived from llamas, called nanobodies, comprise only a small part (a single domain) of conventional antibodies, yet possess full antigen-binding capacity. These nanobodies have shown great potential both as structural tools and as therapeutic agents in a number of diseases caused by protein dysfunction.
A study by Dr. Erwin De Genst and Dr. Marija Iljina reports that llama-derived nanobodies – essentially miniature antibodies – might find therapeutic application in Parkinson’s disease. The nanobodies can bind to harmful protein clumps in the brain, called oligomers, to neutralize toxicity and help prevent cell death. Furthermore, they found that the nanobodies are able to slow down the oligomer’s aggregation reaction.
We are happy to announce that in the near future, Capra Science farm will be housing llamas for development of nanobodies. More information will follow shortly.
The source of the study: https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-017-0390-6